Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.53 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.43 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5921883 | 0.88 | SCN9A (0.55) | SCN9ASCN10A | |
| SCHEMBL4490854 | 0.87 | SCN9A (0.67) | SCN9ASCN10A | |
| SCHEMBL4485082 | 0.82 | SCN9A (0.77) | SCN9ASCN10A | |
| SCHEMBL4509089 | 0.74 | CYP1A2 (0.49) | MAPTKMT2ATHRBGAA | |
| SCHEMBL4498203 | 0.73 | SCN9A (0.86) | SCN9ASCN10A | |
| SCHEMBL29771936 | 0.70 | APLNR (0.53) | SCN9AKMT2A | |
| SCHEMBL18939220 | 0.70 | APLNR (0.53) | SCN9AKMT2A | |
| SCHEMBL13710452 | 0.69 | SCN9A (0.84) | SCN9ASCN10A | |
| SCHEMBL1782081 | 0.69 | GUCY1A1 (0.62) | GUCY1A1GUCY1B1MAPTKMT2ATDP1 | |
| SCHEMBL4491446 | 0.69 | SCN9A (1.00) | SCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | SCN9A 78/4885GUCY1A1 1685/4885GUCY1B1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.